Lannett receives FDA approval for hydrochlorothiazide capsules (LCI) 4.96 : Co announced it has received approval from the FDA of its Abbreviated New Drug Application for Hydrochlorothiazide Capsules, 12.5 mg. Hydrochlorothiazide Capsules, 12.5 mg, is therapeutically equivalent to the reference listed drug, Microzide Capsules, 12.5 mg, of Watson Pharmaceuticals (WPI). Co stated "Hydrochlorothiazide is an important addition to our offering and represents the eighth product approval we have received over the last seven months. We look forward to additional approvals over the next several months."
